跳至主要内容
临床试验/jRCT2031210566
jRCT2031210566已完成不适用

Follow ups of patients in AK1830 Phase II Studies

Asahi Kasei Pharma Corporation0 个研究点目标入组 10 人开始时间: 2022年2月28日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
10
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Other
盲法
Open(masking Not Used)

入排标准

年龄范围
No limit 至 No limit(—)
性别
All

入选标准

  • Patients who provided written informed consent to participate in the clinical study and who met all of the following criteria
  • [1] Patients who participated in the AK1830 Phase II Study and were deemed to require follow up.
  • [2] Patients who fully understand the contents of the study and are capable of providing informed consent

排除标准

  • Patients who met any of the following criteria are to be excluded.
  • [1] Patients who have received their long-term safety outcomes in the AK1830 Phase II Study
  • [2] Patients deemed by the investigator or sub-investigator to be unsuitable for study participation

结局指标

主要结局

-

image evaluations

次要结局

未报告次要终点

研究者

相似试验